Detalhe da pesquisa
1.
In vivo Targeting MEK and TNK2/SRC pathways in PTPN11 driven leukemia.
bioRxiv;
2024 May 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38798550
2.
Ubiquitin-specific protease 7 inhibitors reveal a differentiated mechanism of p53-driven anti-cancer activity.
iScience;
27(5): 109693, 2024 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38689642
3.
Evaluating targeted therapies in older patients with TP53-mutated AML.
Leuk Lymphoma;
: 1-18, 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38646877
4.
Targeting CCL2/CCR2 Signaling Overcomes MEK Inhibitor Resistance in Acute Myeloid Leukemia.
Clin Cancer Res;
30(10): 2245-2259, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38451486
5.
Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AML.
bioRxiv;
2024 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38352538
6.
Mapping the proteogenomic landscape enables prediction of drug response in acute myeloid leukemia.
Cell Rep Med;
5(1): 101359, 2024 01 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38232702
7.
Mass Spectrometry-Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine.
Annu Rev Pharmacol Toxicol;
64: 455-479, 2024 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37738504
8.
The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
Am J Hematol;
98(12): E364-E368, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37815132
9.
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.
Blood Cancer Discov;
4(6): 452-467, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37698624
10.
Ribosomal protein control of hematopoietic stem cell transformation through direct, non-canonical regulation of metabolism.
bioRxiv;
2023 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37398007
11.
Immune cell proportions correlate with clinicogenomic features and ex vivo drug responses in acute myeloid leukemia.
Front Oncol;
13: 1192829, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37361575
12.
CDK12/13 dual inhibitors are potential therapeutics for acute myeloid leukemia.
Br J Haematol;
202(1): 195-198, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37182843
13.
Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.
J Ovarian Res;
16(1): 80, 2023 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37087441
14.
Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia.
Mol Cancer Res;
21(7): 631-647, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36976323
15.
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.
Blood Adv;
7(9): 1899-1909, 2023 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36441905
16.
Chasing leukemia differentiation through induction therapy, relapse and transplantation.
Blood Rev;
57: 101000, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36041918
17.
Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia.
Cancers (Basel);
14(24)2022 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36551626
18.
Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia.
Cold Spring Harb Mol Case Stud;
8(6)2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36307214
19.
Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia.
Mol Cancer Ther;
21(7): 1125-1135, 2022 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35499387
20.
Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib.
Cancer Biol Ther;
23(1): 310-318, 2022 12 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35343367